Michael Benkowitz's most recent trade in United Therapeutics Corp was a trade of 9,375 Common Stock done at an average price of $472.1 . Disclosure was reported to the exchange on Feb. 23, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 472.13 per share. | 23 Feb 2026 | 9,375 | 0 (0%) | 0% | 472.1 | 4,426,181 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 117.76 per share. | 23 Feb 2026 | 9,375 | 9,375 (0%) | 0% | 117.8 | 1,104,000 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2026 | 9,375 | 0 | - | - | Common Stock | |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 472.13 per share. | 23 Feb 2026 | 5,065 | 0 (0%) | 0% | 472.1 | 2,391,318 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 146.03 per share. | 23 Feb 2026 | 5,065 | 5,065 (0%) | 0% | 146.0 | 739,642 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2026 | 5,065 | 0 | - | - | Common Stock | |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 117.76 per share. | 17 Feb 2026 | 14,625 | 14,625 (0%) | 0% | 117.8 | 1,722,240 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2026 | 14,625 | 9,375 | - | - | Common Stock | |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 480.75 per share. | 17 Feb 2026 | 14,625 | 0 (0%) | 0% | 480.8 | 7,031,021 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2026 | 7,875 | 5,065 | - | - | Common Stock | |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 480.75 per share. | 17 Feb 2026 | 7,875 | 0 (0%) | 0% | 480.8 | 3,785,935 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 146.03 per share. | 17 Feb 2026 | 7,875 | 7,875 (0%) | 0% | 146.0 | 1,149,986 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 474.65 per share. | 09 Feb 2026 | 14,625 | 0 (0%) | 0% | 474.7 | 6,941,796 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 117.76 per share. | 09 Feb 2026 | 14,625 | 14,625 (0%) | 0% | 117.8 | 1,722,240 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2026 | 14,625 | 24,000 | - | - | Common Stock | |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2026 | 7,875 | 12,940 | - | - | Common Stock | |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 146.03 per share. | 09 Feb 2026 | 7,875 | 7,875 (0%) | 0% | 146.0 | 1,149,986 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 474.65 per share. | 09 Feb 2026 | 7,875 | 0 (0%) | 0% | 474.7 | 3,737,890 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 470.95 per share. | 02 Feb 2026 | 14,625 | 0 (0%) | 0% | 471.0 | 6,887,679 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 117.76 per share. | 02 Feb 2026 | 14,625 | 14,625 (0%) | 0% | 117.8 | 1,722,240 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2026 | 14,625 | 38,625 | - | - | Stock Options | |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2026 | 7,875 | 20,815 | - | - | Stock Options | |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 470.95 per share. | 02 Feb 2026 | 7,875 | 0 (0%) | 0% | 471.0 | 3,708,750 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 146.03 per share. | 02 Feb 2026 | 7,875 | 7,875 (0%) | 0% | 146.0 | 1,149,986 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2026 | 14,625 | 67,875 | - | - | Common Stock | |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 117.76 per share. | 20 Jan 2026 | 14,625 | 14,625 (0%) | 0% | 117.8 | 1,722,240 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2026 | 14,625 | 53,250 | - | - | Stock Options | |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 471.91 per share. | 20 Jan 2026 | 14,625 | 0 (0%) | 0% | 471.9 | 6,901,656 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 117.76 per share. | 20 Jan 2026 | 14,625 | 14,625 (0%) | 0% | 117.8 | 1,722,240 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2026 | 7,875 | 28,690 | - | - | Stock Options | |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2026 | 7,875 | 36,565 | - | - | Stock Options | |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 471.91 per share. | 20 Jan 2026 | 7,875 | 0 (0%) | 0% | 471.9 | 3,716,276 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 146.03 per share. | 20 Jan 2026 | 7,875 | 7,875 (0%) | 0% | 146.0 | 1,149,986 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 146.03 per share. | 20 Jan 2026 | 7,875 | 7,875 (0%) | 0% | 146.0 | 1,149,986 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 468.12 per share. | 20 Jan 2026 | 2,922 | 1,019 (0%) | 0% | 468.1 | 1,367,836 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 463.26 per share. | 20 Jan 2026 | 2,456 | 9,660 (0%) | 0% | 463.3 | 1,137,768 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 464.06 per share. | 20 Jan 2026 | 2,274 | 7,386 (0%) | 0% | 464.1 | 1,055,264 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 465.11 per share. | 20 Jan 2026 | 1,794 | 5,592 (0%) | 0% | 465.1 | 834,407 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 468.12 per share. | 20 Jan 2026 | 1,573 | 549 (0%) | 0% | 468.1 | 736,347 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 463.26 per share. | 20 Jan 2026 | 1,322 | 5,202 (0%) | 0% | 463.3 | 612,430 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 464.06 per share. | 20 Jan 2026 | 1,225 | 3,977 (0%) | 0% | 464.1 | 568,468 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 466.06 per share. | 20 Jan 2026 | 1,055 | 4,537 (0%) | 0% | 466.1 | 491,697 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 465.11 per share. | 20 Jan 2026 | 966 | 3,011 (0%) | 0% | 465.1 | 449,296 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 469.18 per share. | 20 Jan 2026 | 837 | 182 (0%) | 0% | 469.2 | 392,704 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 458.74 per share. | 20 Jan 2026 | 700 | 13,117 (0%) | 0% | 458.7 | 321,116 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 457.92 per share. | 20 Jan 2026 | 692 | 13,817 (0%) | 0% | 457.9 | 316,879 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 467.09 per share. | 20 Jan 2026 | 596 | 3,941 (0%) | 0% | 467.1 | 278,386 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 466.06 per share. | 20 Jan 2026 | 568 | 2,443 (0%) | 0% | 466.1 | 264,724 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 461.12 per share. | 20 Jan 2026 | 503 | 12,116 (0%) | 0% | 461.1 | 231,943 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 459.87 per share. | 20 Jan 2026 | 498 | 12,619 (0%) | 0% | 459.9 | 229,013 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 469.18 per share. | 20 Jan 2026 | 451 | 98 (0%) | 0% | 469.2 | 211,600 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 458.74 per share. | 20 Jan 2026 | 377 | 7,063 (0%) | 0% | 458.7 | 172,944 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 457.92 per share. | 20 Jan 2026 | 372 | 7,440 (0%) | 0% | 457.9 | 170,345 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 467.09 per share. | 20 Jan 2026 | 321 | 2,122 (0%) | 0% | 467.1 | 149,936 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 461.12 per share. | 20 Jan 2026 | 271 | 6,524 (0%) | 0% | 461.1 | 124,963 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 459.87 per share. | 20 Jan 2026 | 268 | 6,795 (0%) | 0% | 459.9 | 123,244 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 470.37 per share. | 20 Jan 2026 | 156 | 26 (0%) | 0% | 470.4 | 73,378 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 456.86 per share. | 20 Jan 2026 | 116 | 14,509 (0%) | 0% | 456.9 | 52,996 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 470.37 per share. | 20 Jan 2026 | 84 | 14 (0%) | 0% | 470.4 | 39,511 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 456.87 per share. | 20 Jan 2026 | 63 | 7,812 (0%) | 0% | 456.9 | 28,783 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 470.77 per share. | 20 Jan 2026 | 26 | 0 (0%) | 0% | 470.8 | 12,240 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 470.79 per share. | 20 Jan 2026 | 14 | 0 (0%) | 0% | 470.8 | 6,591 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 117.76 per share. | 12 Jan 2026 | 14,625 | 14,625 (0%) | 0% | 117.8 | 1,722,240 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jan 2026 | 14,625 | 82,500 | - | - | Stock Options | |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 479.51 per share. | 12 Jan 2026 | 14,625 | 0 (0%) | 0% | 479.5 | 7,012,769 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jan 2026 | 7,875 | 44,440 | - | - | Stock Options | |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 479.51 per share. | 12 Jan 2026 | 7,875 | 0 (0%) | 0% | 479.5 | 3,776,107 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 146.03 per share. | 12 Jan 2026 | 7,875 | 7,875 (0%) | 0% | 146.0 | 1,149,986 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2026 | 14,625 | 97,125 | - | - | Stock Options | |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 117.76 per share. | 05 Jan 2026 | 14,625 | 14,625 (0%) | 0% | 117.8 | 1,722,240 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 146.03 per share. | 05 Jan 2026 | 7,875 | 7,875 (0%) | 0% | 146.0 | 1,149,986 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2026 | 7,875 | 52,315 | - | - | Stock Options | |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 486.05 per share. | 05 Jan 2026 | 1,669 | 7,863 (0%) | 0% | 486.0 | 811,217 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 490.11 per share. | 05 Jan 2026 | 1,659 | 3,482 (0%) | 0% | 490.1 | 813,094 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 481.86 per share. | 05 Jan 2026 | 1,657 | 12,271 (0%) | 0% | 481.9 | 798,446 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 491.35 per share. | 05 Jan 2026 | 1,201 | 2,281 (0%) | 0% | 491.3 | 590,111 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 488.38 per share. | 05 Jan 2026 | 1,189 | 5,818 (0%) | 0% | 488.4 | 580,679 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 484.99 per share. | 05 Jan 2026 | 1,169 | 9,532 (0%) | 0% | 485.0 | 566,959 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 492.44 per share. | 05 Jan 2026 | 1,110 | 1,171 (0%) | 0% | 492.4 | 546,613 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 486.05 per share. | 05 Jan 2026 | 899 | 4,234 (0%) | 0% | 486.1 | 436,959 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 490.11 per share. | 05 Jan 2026 | 893 | 1,875 (0%) | 0% | 490.1 | 437,669 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 481.86 per share. | 05 Jan 2026 | 891 | 6,608 (0%) | 0% | 481.9 | 429,339 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 482.72 per share. | 05 Jan 2026 | 873 | 11,398 (0%) | 0% | 482.7 | 421,414 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 487.40 per share. | 05 Jan 2026 | 856 | 7,007 (0%) | 0% | 487.4 | 417,218 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 494.27 per share. | 05 Jan 2026 | 797 | 0 (0%) | 0% | 494.3 | 393,935 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 483.80 per share. | 05 Jan 2026 | 697 | 10,701 (0%) | 0% | 483.8 | 337,212 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 480.68 per share. | 05 Jan 2026 | 697 | 13,928 (0%) | 0% | 480.7 | 335,035 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 489.49 per share. | 05 Jan 2026 | 677 | 5,141 (0%) | 0% | 489.5 | 331,385 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 491.35 per share. | 05 Jan 2026 | 647 | 1,228 (0%) | 0% | 491.3 | 317,903 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 488.38 per share. | 05 Jan 2026 | 641 | 3,132 (0%) | 0% | 488.4 | 313,049 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 484.99 per share. | 05 Jan 2026 | 629 | 5,133 (0%) | 0% | 485.0 | 305,061 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 492.44 per share. | 05 Jan 2026 | 598 | 630 (0%) | 0% | 492.4 | 294,482 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 482.72 per share. | 05 Jan 2026 | 471 | 6,137 (0%) | 0% | 482.7 | 227,360 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 487.40 per share. | 05 Jan 2026 | 461 | 3,773 (0%) | 0% | 487.4 | 224,693 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 494.27 per share. | 05 Jan 2026 | 429 | 0 (0%) | 0% | 494.3 | 212,043 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 480.68 per share. | 05 Jan 2026 | 376 | 7,499 (0%) | 0% | 480.7 | 180,737 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 483.81 per share. | 05 Jan 2026 | 375 | 5,762 (0%) | 0% | 483.8 | 181,427 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 493.47 per share. | 05 Jan 2026 | 374 | 797 (0%) | 0% | 493.5 | 184,559 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 489.49 per share. | 05 Jan 2026 | 364 | 2,768 (0%) | 0% | 489.5 | 178,174 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 493.47 per share. | 05 Jan 2026 | 201 | 429 (0%) | 0% | 493.5 | 99,188 | Common Stock |
| United Therapeutics Corp | Michael Benkowitz | PRESIDENT AND COO | Sale of securities on an exchange or to another person at price $ 502.79 per share. | 29 Dec 2025 | 14,625 | 0 (0%) | 0% | 502.8 | 7,353,261 | Common Stock |